GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Type 1 Diabetes

Interventions

DRUG

Semaglutide (Rybelsus®)

7 mg single dose of Rybelsus® by mouth once before each MMTT

DRUG

Placebo

placebo capsule or tablet once before each MMTT.

Trial Locations (1)

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Vanderbilt University Medical Center

OTHER

NCT06338553 - GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | Biotech Hunter | Biotech Hunter